AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biotage

Transaction in Own Shares May 6, 2011

2894_rns_2011-05-06_623993e8-15f2-4c8a-b347-e57336cdbb91.pdf

Transaction in Own Shares

Open in Viewer

Opens in native device viewer

Press release Biotage AB

Contact: SE-751 03 Uppsala Torben Jörgensen, President and CEO Tel+46 18 56 59 00 Tel: +46 707 49 05 84, [email protected] www.biotage.com

Box 8

Uppsala May 5, 2010

Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buyback program in accordance with the Annual General Meeting's resolution to authorize the board to decide on the acquisition and sale of the company's own shares.

At the Annual General Meeting held on 27 April 2011, the board was authorized to decide on the acquisition and sale of the company's own shares up and until the forthcoming Annual General Meeting. The shares acquired may not exceed 10 per cent of the total number of outstanding Biotage shares at any time. The purpose of the repurchase program is to give the board a wider freedom of action in the work with the company's capital structure and thereby improve shareholder value. Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a price within the price interval at any time recorded. Biotage currently does not own any own shares. Previously repurchased 8,848,632 shares have been withdrawn in accordance with the Annual General Meeting's resolution on 27 April 2011.

The information in this press release is of the kind that Biotage AB (publ) may be required to make public according to the Securities Market Act and/or Financial Instruments Trading Act. The information was released for publication at 8.30 am on May 6, 2011.

About Biotage:

Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 272 employees and had sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website:www.biotage.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.